In focus · trending topic

Triplet Oral Therapy

3 stories · following the connections

Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin

By Nasdaq OMXAug 8, 2017, 11:30 AM UTC

Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin

By Nasdaq OMXMar 7, 2017, 1:31 PM UTC

Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin

By Nasdaq OMXMar 7, 2017, 1:30 PM UTC